All In Biotech

Drug Trial Radar · NCT05024045

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Sep 30, 2021

Primary completion

Jun 14, 2023

Study completion Mar 2, 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Aug 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, B-cell Marginal Zone
  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma
  • B-cell Lymphoma
  • Waldenstrom Macroglobulinemia
  • Lymphoma, Mantle-Cell

Interventions

  • LOXO-338Drug

    Oral

  • PirtobrutinibDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of oral LOXO-338Time frame: Cycle 1 (28 Days)
  2. Part 1 - To determine the effect of LOXO-338 on response ratesTime frame: Estimated up to 2 years
  3. Part 2 - To determine the safety and tolerability of LOXO-338 when given in combination with pirtobrutinibTime frame: Cycle 2 (28 Days)

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • University of California San Francisco, Medical Center at Paranassus

    San Francisco, California

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Emory University

    Atlanta, Georgia

  • Indiana Blood & Marrow Transplantation (IBMT)

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Westwood, Kansas

  • Tufts Medical Center

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Swedish Medical Center

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • CHRU de Montpellier-Hopital St Eloi

    Montpellier, France

  • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu

    Nantes, France

  • Institut Curie

    Paris, France

  • Centre hospitalier universitaire de Haut Leveque

    Pessac, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, Cedex, France

  • L'Institut Universitaire du Cancer de Toulouse Oncopole

    Toulouse, Cedex 9, France

  • IRCCS - AOU di Bologna

    Bologna, Italy

  • Pratia MCM Krakow

    Krakow, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

    Warsaw, Poland

  • Centrum Medyczne Pratia Poznan

    Skorzewo, Poznan, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.